Resources from the same session
Time to response in patients with ALK+ NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies
Presenter: Leena Gandhi
Session: NSCLC, metastatic
Resources:
Abstract
Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)
Presenter: Leora Horn
Session: NSCLC, metastatic
Resources:
Abstract
Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung
Presenter: Vamsidhar Velcheti
Session: NSCLC, metastatic
Resources:
Abstract
Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)
Presenter: Scott Antonia
Session: NSCLC, metastatic
Resources:
Abstract
Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010
Presenter: Roy S. Herbst
Session: NSCLC, metastatic
Resources:
Abstract
Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057
Presenter: Martin Reck
Session: NSCLC, metastatic
Resources:
Abstract
LURET study: Phase 2 study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC)
Presenter: Atsushi Horiike
Session: NSCLC, metastatic
Resources:
Abstract
Lung sarcomatoid carcinoma (LSC) harbors targetable genomic alterations and high mutational burden as observed by comprehensive genomic profiling (CGP)
Presenter: Balazs Halmos
Session: NSCLC, metastatic
Resources:
Abstract
Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update
Presenter: Fabrice Barlesi
Session: NSCLC, metastatic
Resources:
Abstract
Invited discussant abstracts LBA48, 1215PD, 1216PD, 1217PD, and 1218PD
Presenter: Fiona Blackhall
Session: NSCLC, metastatic
Resources:
Presentation
Webcast